February 3 (Reuters) – British pharmaceutical GlaxoSmithKline Plc is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute to the effort to develop a vaccine for the coronavirus outbreak, GSK and CEPI said on Monday.
GSK will make its "adjuvant platform technology" available for the development of a vaccine against the 2019-nCoV virus, according to the statement.
The use of adjuvant allows the production of more doses of vaccine and, therefore, would increase availability for more people.
GSK will engage with CEPI-funded entities, with the first of these agreements signed between the British pharmaceutical company and the University of Queensland in Australia, the statement added.
The rapid flu virus killed more than 300 people in China, spread to more than two dozen countries and caused the world's second largest economy to be hit by travel restrictions and company shutdowns.
There is currently no vaccine available against the coronavirus, but several organizations, including CEPI, a public-private body based in Norway, are working on developing one.
The Foundation of the Pasteur Institute in France said on Friday that it had set up a task force to develop a vaccine against the virus in 20 months, while Germany's research minister said he expected the vaccine to be developed within "a few months. ".
(Reporting by Kanishka Singh in Bengaluru)